Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients

Sayan M., Gunduz A., Ersoz G., Inan A., Deveci A., Ozgur G., ...More

HIV CLINICAL TRIALS, vol.17, no.3, pp.109-113, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.1080/15284336.2016.1153303
  • Journal Name: HIV CLINICAL TRIALS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.109-113
  • Keywords: Hiv-1 Integrase, Integrase Inhibitors, Raltegravir, Elvitegravir, Dolutegravir, Drug Resistance, Dna Sequencing, ANTIRETROVIRAL-NAIVE PATIENTS, NATURAL POLYMORPHISMS, HIV-1, INDIVIDUALS, THERAPY, UPDATE, TURKEY
  • Bursa Uludag University Affiliated: Yes

Abstract

Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients.